We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Mr R.. sad times I’m already in the ally waiting on this to get above my average…
Selling 10 mins a share.. tho, be good money “soon”
Especially at keyboard prices
Seems some history with company called arisaph. This grant description has compound based on velcade with same number.
https://grantome.com/grant/NIH/R41-CA156930-01A1
other side effects
https://reference.medscape.com/drug/velcade-bortezomib-342256
was wondering what side effects so turned to Mr Google. Found the following link.
https://somepomed.org/articulos/contents/mobipreview.htm?13/8/13451
Velcade could goto grade 5 if treatment continued.
Too far lads….. too far
must have a setting for the old meat flute, always plays a delightful tune.
Do we have to swallow ?
I’ll sell one share when PreCision pays off and buy you this one?
Comes with a rumba beat button and organ mode. A lot here are masters at playing with an organ I reckon…..
https://www.argos.co.uk/product/9370487?istCompanyId=a74d8886-5df9-4baa-b776-166b3bf9111c&istFeedId=30f62ea9-9626-4cac-97c8-9ff3921f8558&istItemId=iatwatqxi&istBid=t&&cmpid=GS001&_$ja=tsid:59157%7Cacid:629-618-1342%7Ccid:9563523552%7Cagid:102230988150%7Ctid:pla-1162122878079%7Ccrid:423314716928%7Cnw:g%7Crnd:9359170650145981708%7Cdvc:m%7Cadp:%7Cmt:%7Cloc:9046549&utm_source=Google&utm_medium=cpc&utm_campaign=9563523552&utm_term=9370487&utm_content=shopping&utm_custom1=102230988150&utm_custom2=629-618-1342&gclid=CjwKCAiA55mPBhBOEiwANmzoQvQvj4lvg9qkW36EDhhjIWKnB939N3ZWaJ9BXKisR0c_h0zKJwtpJBoCw0AQAvD_BwE&gclsrc=aw.ds
top, thanks.
Mr R...you owe me a keyboard, this one had tea sprayed over it.
It’s velcade.
I found this bit very very interesting;
“Proteasome inhibitors have a market that is expected to grow to $2.3bn by 2026[1], despite limited regulatory approvals of other molecules in this class due to their serious toxicities.”
This to me is a possible nod to AVA6000 seriously reducing toxicity via PreCision in the Pro-Doxorubicin trial. As is often stated the fact of the matter is the car was a great idea; the model T made cars more user friendly and accessible and massively increased the market size and so the Model T became massively successful. I believe PreCision will have the same effect on the Chemotherapy market, increasing the useability and market size of each therapeutic. And that’s before you add an affimer into the game with T-Mac. We few, we (mostly) happy few, we band of weirdos, could really be in early doors here on something great.
For balance it could all be total crap and we’ll all be sucking richards for a fiver a go in back alley ways to pay the rent. But I don’t think so.
Yeah odd not mentioned in the RNS but from the Sept interims RNS it was Velcade...
"The next most advanced pre|CISION™ pro-drug is AVA3996, a FAP-activated analogue of Velcade, Takeda's proteasome inhibitor which comes off patent in 2022. The global proteasome inhibitors market size is expected to be worth $1.7 billion by 2023 (source) and Velcade represents just over half of that market. As with all chemotherapies the benefit of these drugs is limited by toxicities and tolerability for patients. In the case of Velcade, there are significant side effects such as peripheral neuropathy which has limited its approval, principally to multiple myeloma. A potentially safer proteasome inhibitor, such as AVA3996, could win significant market share for the treatment of multiple myeloma and also be used to treat solid tumours, such as pancreatic cancer. Pancreatic cancer also exhibits the highest level of FAP activity of any solid tumour and therefore a FAP activated pro-drug could have significant potential in this area of high unmet need."
I've always thought it was Velcade - maybe AS mentioned it before. Odd it didn't say it in RNS.
Looks like Velcade (bortezomib), Kyprolis (carfilzomib) or Ninlaro (ixazomib).
With Velcade coming off patent this year it's probably the most likely. GLA
anyone know if a generic is being used with Precision for AVA3996, and if so which one or ones.